Post COVID-19 condition after Wildtype, Delta, and Omicron variant SARS-CoV-2 infection and vaccination: pooled analysis of two population-based cohorts

Introduction

Post COVID-19 condition (PCC) is an important complication of SARS-CoV-2 infection, posing a substantial burden on health care systems worldwide.^1,2 Population-based studies have estimated that about 20–30% of non-vaccinated individuals with a confirmed Wildtype SARS-CoV-2 infection develop PCC,³ defined as symptoms persisting beyond three months after infection and not explained by an alternative diagnosis.¹ As of writing, half a billion SARS-CoV-2 infections have been diagnosed worldwide,⁴ leading to more than 144 millions of people estimated to have been affected by PCC in 2020 and 2021.² While most individuals with PCC are mildly affected and recover within months after infection,^2,5 some suffer from protracted symptoms with a substantial impact on daily activities, social and professional life.³ With the global implementation of vaccination campaigns and the emergence of novel SARS-CoV-2 variants of concern, future management of the pandemic will thus likely depend on the incidence of PCC in vaccinated individuals infected with novel variants.

Current evidence suggests that the risk to develop PCC is relevantly reduced by vaccination with mRNA-based or adenovirus vector-based vaccines.⁶ Several studies have been conducted using different study designs and populations, with the majority finding that the risk of PCC is approximately halved in vaccinated compared to non-vaccinated individuals.^7–17 While most studies evaluated symptoms persisting for more than four weeks^8,9,17 or more than 12 weeks^{10,12,13,15,16} after SARS-CoV-2 infection, only three assessed symptoms beyond six months and identified a lower⁷ or no^11,14 risk reduction with vaccination.

Meanwhile, the evidence regarding infection with novel SARS-CoV-2 variants remains limited and inconsistent. While there is some evidence that infections with the Omicron variant reduced the risk of developing PCC compared to the Delta¹⁸ or any previous variant¹⁹, evidence from another study demonstrated a reduced risk with the Alpha variant, but not with the Delta or Omicron variant compared to Wildtype SARS-CoV-2.⁹ However, all three studies drew from specific samples not representative of the general population, and none of them has evaluated PCC for more than 12 weeks after infection. Therefore, more knowledge regarding the expected risk reduction through infection with newer variants and the preventive effects of vaccination on PCC in the longer-term is urgently needed.

This study aimed to evaluate the prevalence and severity of PCC in individuals infected by Wildtype, Delta, and Omicron SARS-CoV-2 with and without prior vaccination. Specific objectives were to assess the difference in risk of developing PCC with emerging variants and vaccination, evaluate changes in symptom severity, and identify prevalent symptom clusters and their evolution across pandemic waves. Thereby, we aim to inform public health policies and vaccination strategies worldwide for the future management of the pandemic.

Methods

Results

We included data from 1045 Zurich SARS-CoV-2 Cohort participants and 305 Corona Immunitas participants reporting a SARS-CoV-2 infection with six months of follow-up (Table 1, Supplementary Figure S1, Supplementary Tables S4–5). Median follow-up was 183 days (interquartile range [IQR] 182– 186 days) across all participants. Zurich SARS-CoV-2 Cohort participants were slightly older on average, with a median age of 51 years (IQR 35–66) compared to 43 years (30–54) among Corona Immunitas participants. The proportion of female participants was 50.7% and 58.7%, respectively. Participants more frequently reported the presence of at least one medical comorbidity in the Zurich SARS-CoV-2 Cohort (29.5%) compared to Corona Immunitas (14.1%). 232 (77.1%) Corona Immunitas participants reported to have received at least one COVID-19 vaccine prior to infection, among which 173 (74.6%) had received one or two doses, and 59 (25.4%) had received three doses. Almost all (n=231, 99.6%) had received a mRNA-based vaccine (i.e., BNT162b2 or mRNA-1273) while one participant had received a vector-based vaccine (i.e., JNJ-78436735). A previous SARS-CoV-2 infection was reported by 36 (11.8%) of Corona Immunitas participants.

Overall, 25.3% (95% CI 22.7–28.0%, n=264) of individuals with Wildtype SARS-CoV-2, 17.2% (11.0– 25.8%, n=17) of Delta-infected, and 13.1% (9.2–18.4%, n=27) of Omicron-infected individuals were affected by PCC six months after their last infection. The proportion of participants with PCC among non-vaccinated individuals infected with the Delta (21.6%, 11.4–37.2%, n=8) and Omicron (21.9%, 11.0– 38.8%, n=7) variants were similar compared to Wildtype infection without prior vaccination. Among individuals that had received at least one vaccination dose prior to infection, 14.8% (8.0–25.7%, n=9) had PCC after Delta, and 11.1% (7.2–16.7%, n=19) after Omicron infection. No clear patterns in PCC-related symptoms were observed across individuals infected with the different variants (Supplementary Figure S2).

When assessing the association between infection with different SARS-CoV-2 variants and prior vaccination with PCC at six months, there was strong evidence for a reduction in the risk among vaccinated individuals infected by the Omicron variant (OR 0.42, 95% CI 0.24–0.68, p=0.0008) compared to non-vaccinated participants infected with Wildtype SARS-CoV-2, based on multivariable logistic regression analyses adjusted for age, sex, presence of comorbidities, hospitalization due to COVID-19, and prior infection (Figure 1). Meanwhile, there was weak evidence for a risk reduction among vaccinated individuals infected with Delta (OR 0.55, 0.25–1.08, p=0.11), but no evidence for a reduction in the risk among non-vaccinated individuals infected by the Delta (OR 0.84, 0.34–1.87, p=0.69) or Omicron (OR 0.87, 0.33–2.06, p=0.77) variant. In sensitivity analyses including variant and vaccination as separate variables, results were similar for the association of Delta (OR 0.92, 0.44–1.83, p=0.83) and Omicron (OR 0.78, 0.35–1.65, p=0.54) infection, as well as prior vaccination with PCC (OR 0.55, 95% CI 0.26–1.19, p=0.12; Supplementary Figure S3).

• Download figure
• Open in new tab

Figure 1: Association of Delta and Omicron SARS-CoV-2 infection and prior vaccination with post COVID-19 syndrome six months after SARS-CoV-2 infection.

Panels A and B show odds ratios and adjusted risk differences among non-vaccinated and vaccinated individuals infected with the Delta or Omicron variant compared to non-vaccinated individuals infected by SARS-CoV-2, based on multivariable logistic regression models adjusted for age, sex, presence of comorbidities, initial hospitalization due to COVID-19, and prior infection. Panels C and D show odds ratios for having received one or two vaccine doses or three doses prior to infection and for having been vaccinated less than six months prior or six or more months prior to infection with the Delta or Omicron variants, based on multivariable logistic regression models adjusted for age, sex, presence of comorbidities, initial hospitalization due to COVID-19, and prior infection. aRD = adjusted risk difference, CI = confidence interval, OR = odds ratio, Ref. = reference group.

In analyses stratified by the number of vaccine doses received prior to infection, there was no evidence for a difference between individuals that had received one or two vaccine doses and individuals that had received three doses among individuals infected with the Delta variant, while there was a tendency for a stronger effect with three (OR 0.30, 0.10–0.70, p=0.013) compared to one or two doses (OR 0.49, 0.26– 0.87, p=0.020) with the Omicron variant (Figure 1). The risk independent of variant was equally reduced for both one to two doses and three doses compared to non-vaccinated individuals, however with high uncertainty (Supplementary Figure S3). When evaluating the timing since the last vaccine dose at infection, there was no evidence for a difference between individuals that were vaccinated six or more months prior, and individuals vaccinated less than six months prior to infection among individuals infected with the Delta and the Omicron variant (Figure 1). Findings were similar in a sensitivity analysis of associations independent of variants (Supplementary Figure S3).

In terms of the severity of PCC-related symptoms at six months, there were similar patterns across groups infected by different variants and with and without prior vaccination (Figure 2). In accordance with the overall prevalence of PCC, we observed lower prevalences of individuals reporting one to two, three to five, and six or more PCC-related symptoms among vaccinated individuals infected with the Omicron variant compared to other groups. Sensitivity analyses using different severity classifications resulted in similar findings (Supplementary Figure S4). While the risk among vaccinated Omicron-infected individuals was lower for those reporting three or more symptoms, 4% (n=7) still reported such symptoms after six months. In multivariable multinomial logistic regression analyses, there was strong evidence for a reduction in those reporting one or two symptoms among vaccinated Omicron-infected individuals compared to non-vaccinated Wildtype-infected individuals (OR 0.39, 95% CI 0.21–0.74, p=0.0038), while the statistical evidence for a reduction of those reporting three to five (OR 0.44, 0.16–1.19, p=0.11) and six or more symptoms (OR 0.50, 95% CI 0.11–2.21, p=0.36) was insufficient (Table 2, Supplementary Tables S6–8).

• Download figure
• Open in new tab

Figure 2: Prevalence of post COVID-19 condition six months after infection at different levels of severity in terms of symptom count.

Analyses were stratified by SARS-CoV-2 variant and vaccination status. Points represent point estimate and error bars represent 95% Wilson confidence intervals for estimated proportions.

Cluster analyses resulted in the identification of four clusters with different patterns of PCC-related symptoms (Figure 3). Based on the predominant symptom patterns in each cluster, we categorised them into groups with diverse systemic (n=219 of participants with PCC), neurocognitive (n=47), cardiorespiratory (n=23), and musculoskeletal symptoms (n=19). Meanwhile, certain symptoms were prevalent in all four clusters, such as fatigue, post-exertional malaise, headache, and taste or smell disturbances. In sensitivity analyses assuming five or six clusters, additional groups of individuals predominantly affected by gastrointestinal disturbances or hair loss, and by vertigo or dizziness were identified (Supplementary Figures S5–6). Across infections with different variants, we observed no clear differences in the proportion of participants belonging to each cluster (Figure 3). Female participants were more prevalent in the neurocognitive and cardiorespiratory clusters and older participants and individuals with comorbidities were more prevalent in the cardiorespiratory and musculoskeletal clusters, while the majority of participants with diverse systemic symptoms reported having one PCC-related symptom (Supplementary Table S9).

• Download figure
• Open in new tab

Figure 3: Prevalence of specific post COVID-19 condition-related symptoms six months after SARS-CoV-2 infection across symptom clusters.

Four clusters of individuals with post COVID-19 condition at six months after infection were identified based on multiple correspondence and hierarchical cluster analyses, consisting of individuals with (1) diverse systemic symptoms and lower symptom count, and with (2) predominantly neurocognitive, (3) cardiorespiratory, or (4) musculoskeletal symptoms. Panel A depicts distributions of specific post COVID-19 condition-related symptoms across clusters. Panel B shows the proportion of individuals belonging to each cluster across infections with Wildtype, Delta, and Omicron SARS-CoV-2. Points represent point estimate and error bars represent 95% Wilson confidence intervals for estimated proportions.

In this pooled analysis of 1350 SARS-CoV-2-infected individuals from two population-based cohorts, we found that infection with the Omicron variant and prior vaccination were associated with a lower risk of PCC six months after infection, while the risk among non-vaccinated individuals infected with the Delta or Omicron variant was similar to those infected with Wildtype SARS-CoV-2. We found no differences in the occurrence of PCC between individuals having received one or two vaccine doses and individuals having received three vaccine doses, and between individuals last vaccinated more or less than six months prior infection. Compared to non-vaccinated individuals infected with Wildtype SARS-CoV-2, the severity of PCC symptoms was lower among vaccinated individuals infected with the Omicron variant, but the risk for PCC even of high severity was still present.

To our knowledge, this study is the first to simultaneously evaluate the impact of prior vaccination and infection with the Omicron variant on developing PCC up to six months after infection. In our study, the risk among non-vaccinated individuals infected with the Omicron variant was reduced by approximately 23% compared to those infected by Wildtype SARS-CoV-2, corresponding to an absolute reduction of about 3 in 100 infected individuals. Among vaccinated individuals, the risk was reduced by 45% and 58% for Delta and Omicron infection, respectively, compared to non-vaccinated Wildtype-infected individuals. This corresponds to an absolute risk reduction in Omicron-infected of about 4 in 100 compared to vaccinated Delta-infected individuals and of 10 in 100 compared to non-vaccinated Wildtype-infected individuals. These estimates are in line with a relative risk reduction of 33% between infections with Omicron and prior variants at three months reported in a previous study.¹⁹ While one further study reported no association of pooled Omicron and Delta infection with PCC compared to Wildtype infection at four weeks,⁹ another reported a stronger risk reduction between Omicron and Delta infection among vaccinated individuals.¹⁸ They also found a stronger risk reduction among those vaccinated more than three months prior infection compared to those infected less than three months before. In our study, we did not identify a difference depending on whether the last vaccination was received more or less than six months prior to infection. To date, no study investigated potential effects on severity of PCC. Further evidence from representative population-based studies is thus necessary to better estimate the reduction in the risk and severity of PCC in the longer-term while accounting for vaccination. While it cannot be excluded that future variants may bear a higher risk for PCC, this population-based study provides important early evidence on its longer-term risk and severity with the Omicron variant.

There is substantial heterogeneity between existing studies evaluating the effects of vaccination on PCC.⁶ Our findings together with those from others imply that vaccination may reduce the risk of PCC by up to 50%,^{7–9,12,13,15–17} with an estimated relative risk reduction of 52% among Omicron-infected, and 35% among Delta-infected in our study. Despite important differences in study populations, study designs, analytical methods, and definitions of PCC across existing studies, our estimates are in line with previous evidence, albeit of smaller magnitude compared with one other study simultaneously investigating differences between SARS-CoV-2 variants and prior vaccination among non-hospitalised healthcare workers.⁹ The accumulating evidence on potential preventive effects of vaccination on PCC has important implications for vaccination strategies and may be used to inform and positively influence individual decisions regarding booster vaccinations. However, a rigorous evaluation of the evidence, taking into account the substantial heterogeneity in study designs and the time periods during which they took place, is warranted prior to issuing recommendations regarding the prevention of PCC through vaccination.

In cluster analyses, we identified four distinct clusters of PCC-related symptoms across different variants, which we categorised as diverse systemic, neurocognitive, cardiorespiratory, and musculoskeletal symptoms. One study so far has investigated symptom clusters in the context of different SARS-CoV-2 variants.³³ The authors reported three main emerging PCC symptom clusters (i.e., central neurological, cardiorespiratory, and systemic/inflammatory), while total number of identified clusters and cluster profiles varied across Wildtype, Alpha, and Delta variants. In our study, we found no substantial variation in the prevalence of symptom clusters across infections with different variants, but relevant variation in participant characteristics across clusters. Further studies have investigated the clustering of PCC-related symptoms, leading to the identification of similar groups with neurocognitive, cardiorespiratory, musculoskeletal and pain-related, and systemic or diverse symptoms.^34,35 Our findings are thus in line with existing evidence, and suggest that some symptoms may be common to all presentations of PCC, while there may be distinct phenotypes of PCC that may also have different pathophysiological explanations or require different clinical management or specific treatment.

This study has several key strengths, including the representative, population-based sample, and the prospective design, alongside a longer-term perspective of PCC six months after infection. Meanwhile, several limitations have to be considered when interpreting the results. First, we pooled data from two different but closely aligned cohorts. Due to the different sampling, recruitment, and timeframes of data collection, there may still be differences between cohorts that we could not fully account for in adjusted analyses. Second, selection may have occurred in both cohorts if participants with long-term symptoms were more likely to be enrolled or complete the questionnaire. However, in the Zurich SARS-CoV-2 Cohort, participants were enrolled prior to the possible occurrence of PCC, and there was minimal loss to follow-up. Corona Immunitas was a highly public, governmentally supported seroprevalence study using a random population sample, from which we included all individuals with diagnosed infection. While some asymptomatically infected individuals in this study may not have sought testing and thus were excluded, we consider the probability of relevant selection bias with respect to the findings to be low. Third, we relied on self-reported measures and could not perform a clinical validation of the relation of symptoms with initial SARS-CoV-2 infection or alternative diagnoses. While information bias cannot be excluded, we consider its potential effect on our findings to be minimal. Fourth, we did not have direct genetic data from viral sequencing and may have misclassified some participants infected with the Delta or Omicron variant based on our cut-off timeframes. Fifth, we determined severity of PCC based on symptom count and EQ-VAS, of which the first may not be a direct correlate of severity and the latter may be influenced by baseline health status. While we tried to account for this in sensitivity analyses leading to broadly similar findings, results may still be confounded. Sixth, vaccinated participants were almost exclusively vaccinated with mRNA-based vaccines, so that our findings may not be fully generalisable to other vaccine types. Seventh, the study was not adequately powered to investigate differences in associations between individuals vaccinated once or twice and individuals that received three vaccine doses, leading to substantial statistical uncertainty. Last, the exploratory cluster analyses bear various limitations inherent in the structure and parametrisation of the model. Identified clusters are probabilistic and sample-bound, and may not coincide with phenotypes of PCC encountered in clinical practice. While our findings align with those by others, further research is necessary to more clearly identify different phenotypes based on their clinical and pathophysiological presentation.

In conclusion, this study demonstrated that infection with Omicron SARS-CoV-2 among individuals with prior vaccination is associated with a substantially reduced risk of PCC at six months post-infection compared to infection with Wildtype SARS-CoV-2 in non-vaccinated individuals, respectively. While the risk of developing PCC appears to persist in the context of vaccination and novel variants, the reduction in risk through vaccination was of greater magnitude than with infection by Delta or Omicron SARS-CoV-2. This information should be considered in vaccination strategies, further vaccine development, and the planning of public health measures for future pandemic waves.

Author contributions

TB, DM, JF, and MAP conceived and designed the Zurich SARS-CoV-2 Cohort study. MK, RA, AF, VvW, JF, EA, and MAP conceived and designed the Corona Immunitas seroprevalence study. JF, EA, and MAP supervised the project. TB, DM, MK, RA, AF, and VvW provided administrative, technical, or logistical support for the studies. All authors had full access to the data. DM, TB, and MK accessed and verified the underlying data. TB and DM conducted the statistical analyses. All authors contributed to the interpretation of the findings. TB and DM drafted the first version of the manuscript. All authors critically revised the manuscript for important intellectual content. All authors accept full responsibility for the content of the paper and have seen and approved the final version.

Data sharing

Deidentified individual participant data underlying the findings of this study will be available for researchers submitting a methodologically sound proposal to achieve the aims of the proposal after publication of this article. Proposals should be directed at the corresponding author (Prof. Dr. Milo A. Puhan, miloalan.puhan{at}uzh.ch).